Skip to main content
. Author manuscript; available in PMC: 2020 Jul 19.
Published in final edited form as: Hepatology. 2018 Jun 12;68(2):574–589. doi: 10.1002/hep.29844

FIG. 7.

FIG. 7.

Human TCR-T cells have potent and specific cytotoxicity against HepG2 tumor cells. (A) One hundred thousand TCR-T cells were cocultured overnight in triplicate with the indicated tumor cells at E/T ratios. The killing efficacy of HepG2 tumor cells by human TCR-T (both CD8 and CD4) cells was measured by LDH assay. (B) Dose-dependent killing of AFP+HepG2 tumor cells was shown by TCR-T cells. (C) Donor CD8 and CD4 TCR-T cells were separated by magnetic beads after TCR transduction. (D) Coculture of the mock-transduced, CD4, or CD8 TCR-T cells with HepG2 tumor cells. Pictures were taken at 2 and 24 hours after coculture. (E) LDH assay was conducted at 24 hours after coculture to measure the killing effect. Statistical analysis was done with t test. (F) PI staining of TCR-T and HepG2 tumor cell cocultures after 24 hours to reveal dead cells. The experiment was repeated trice with similar data.